Why the study?
Does catheter-based radiofrequency ablation of renal nerves reduce blood pressure in patients with drug-treated resistant hypertension?
Does catheter-based radiofrequency ablation of renal nerves reduce blood pressure in patients with drug-treated resistant hypertension?
Catheter-based renal denervation is recommended as a therapeutic option for patients with resistant hypertension uncontrolled by standard lifestyle and pharmacological therapies.
Answers are grounded in this paper and cite their sources.
Supports renal denervation as adjunctive option in resistant hypertension; confirms randomized efficacy and extends to guideline-endorsed practice.
Current evidence from the available clinical trials strongly support the notion that catheter-based radiofrequency ablation of renal nerves reduces blood pressure and improves blood pressure control in patients with drug-treated resistant hypertension, with data now extending out to 36 months. Accordingly, renal denervation can be considered as a therapeutic option in patients with resistant hypertension, whose blood pressure cannot be controlled by a combination of lifestyle modification and pharmacological therapy according to current guidelines. The fact that renal denervation also reduces whole-bodysympathetic nerve activity suggests that this therapy may also be beneficial in other clinical states characterized by sympathetic nervous system activation-this may ultimately lead to new indications.
No takes yet. Share an insight, caveat, or question.
Mahfoud et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: